

### New CLT Laboratory Project Outline

June 25 2018 Miraca Holdings

#### Business environment



# Demographics Social security Hospital management

Advancements in medical technology

Change in expectations of companies

- Need to curb increasing medical costs
- Increase in aging population
  - Increasing trend in sample volume
- Demand for reduced testing fees
- Decrease in working population



Provide high quality testing at a low price

#### Business environment



Demographics
Social security
Hospital
management

# Advancements in medical technology

Change in expectations of companies

- Advanced/expensive medical treatment
  - Genome, regenerative medicine etc.
- Technological progress in life science field

Innovative testing for cutting edge medical care

#### Business environment



Demographics
Social security
Hospital
management

Advancements in medical technology

Change in expectations of companies

- Incorporating ESG
  - BCP Support

- Contributions to society/ local communities
- Eco-conscious
- Business continuity in case of natural disasters

#### For continuous mid/long term growth



#### Mid-long term targets

- 1. Full automation
- 2. Utilize IT-AI
- 3. Efficient workflow
- 4. Seismic resistance
- 5. Reinforce R&D
- 6. Green facility grounds and solar panels
- 7. Welfare enrichment

- Improve testing quality/speed
- Cost reduction
- Labor-saving operation
- **BCP**
- Future business creation
- Lower environmental burden
- Employee-friendly working conditions

#### Current status of Hachioji Lab complex



#### Hachioji Lab Complex

- Multiple extensions added since 1980
- Multi-story buildings, with shuttle bus transportation between labs
- Outdated IT system (over 40 years from launch)

Hachioji
1st Laboratory

Center for Genetic & Chromosomal Analysis

MUQS Laboratory

Fujirebio Inc. Hachioji
Office

Hachioji
3rd Laboratory

Limited
Potential for
Growth

**Complex Operations** 

Outdated facility and IT system

Business growth and eco-friendly initiatives are difficult with the existing facility



#### **Corporate philosophy**

Create new value in Healthcare and contribute to the prosperity of people.

To ensure the future needs of society can be met, Miraca Group will build a cutting edge laboratory with outstanding technical ability and increased efficiency to serve as their flagship facility



#### New CLT Laboratory - Outline







(Up to 300,000 samples per day)

Test Admissions General Testing Esoteric Testing

**New Operating System** 

R&D Building

Fundamental research

Development of test items and services

Welfare Management
Building

Multipurpose Hall Conference Rooms Nursery



**Seismic Base Isolation** 



**Earthquake Resistance** 



#### General Testing Concepts



- 1. **Full automation** and 24 hour operations to increase efficiency
- 2. World's largest laboratory with mass testing capabilities
  - Increase of general tests processed, as per "Transform! 2020"
- 3. Establishment of local depots, **overall efficiency** increased
  - \*Local depots: Mainly for admission of samples and separating cells/serum
    - New depots planned for major locations in the Kanto area
    - Some equipped with STAT labs (emergency testing capabilities)
    - Current Kanto satellite lab to be converted into a local/ STAT lab

#### General Testing – Fully Automated




- Use knowledge from SRL Advanced Lab. Azabu
- Improve test quality and reduce costs

#### Reduce human error in each test category

#### **Conventional Method**







#### General Testing – Work with local depots



- Consolidate general tests from the Kanto area in the new CLT Laboratory
- Depots admit samples and separate blood serum, before sending on to the CLT laboratory
- Cost reduction through mass processing and full automation







#### **Esoteric Testing Concepts**



#### Facilities and environment to support the cutting edge testing

- Introduce state-of-the-art testing facilities for expanding on and advancing test items
- Ensure potential for flexible growth by integrating automation and robots
- Increase efficiency and space through effective layout changes

#### 2. Improve **Testing Quality**

- Keep movement of samples to a minimum for efficiency and to give leeway
- Ensure safety and test quality improvements


#### 3. Incorporate **AI technology**

- Efficiency through automation/semi-automation of the testing process
- Reduce labor through AI/image recognition technology (testing categories such as chromosomal tests/cell-mediated immunity tests etc.)

#### **New Operating System**



- Full-scale upgrade of IT system (utilization of the existing software)
- Reduce effect on clients by continuing use of existing interface with clients' systems
- Create optimal environment for business development using cloud and our own data center



#### R&D Building Concept



## Fundamental research for new business creation

- Focal points of the group's fundamental research and also promotion of open innovation
  - 1. Innovative analytics platform
  - 2. Supporting medical advancements, personalized medicine and technological developments
  - 3. Medical information, informatics, AI

#### 2. Development and introduction of **new test items**

- New test items for the CLT Business
- Development is in close proximity to test sites to ensure swift implementation

#### 3. Next Generation Platform

Developing a next generation platform for the IVD Business

#### Facility Design Concept



#### Connect

- Connect with the future through cutting-edge technology
- Connect the world through open communications
- Connect people in an environment that sparks innovation

#### Show



#### Build


- Show the world the next generation CLT laboratory
- Show the future of safe and reliable R&D facilities
- Show the world a positive working environment



- Build welfare and nursery facilities to support the next generation
- Build a company with a progressive working atmosphere



Business continuity even in the event of a disaster







#### Total Project Scale and Schedule

#### Outline of buildings



	Laboratory	R&D	Welfare Management			
Floors	3 • 1F: Sample admissions, General tests • 2,3F: Esoteric tests	4	<ul> <li>Reception, visitors' room, conference room</li> <li>Hall, research/study room, cafeteria</li> </ul>			
Total Floor Space (approximately)	46,000m <sup>2</sup>	10,000m <sup>2</sup>	10,000m <sup>2</sup>			
Outline	<ul> <li>Seismic isolation</li> <li>General tests</li> <li>Full automation</li> <li>Esoteric tests</li> <li>Cutting edge instruments</li> <li>Potential for future growth or flexibility of use</li> </ul>	<ul> <li>Seismic isolation</li> <li>Miraca Research Institute</li> <li>IVD</li> <li>Next generation platform</li> <li>CLT</li> <li>New test items</li> </ul>	<ul> <li>Earthquake resistance</li> <li>Multipurpose Hall         Conference room (300 seats)     </li> <li>Accepts visitors         Workspaces visible to visitors     </li> <li>Facility grounds full of greenery</li> </ul>			

● Site area: 122,000㎡ Total Floor Space: 66,000㎡

#### Total Scale of Project



Real estate

JPY 50 billion

Land

JPY 13 billion

Buildings
(including related equipment)

JPY 37 billion

Off balance sheet under real estate financing is also under consideration

Total project scale
JPY 75 billion

CAPEX

Instrument and Core IT system

JPY 25 billion

Instrument

JPY 17 billion


Core IT system

JPY 8 billion

#### Cost reduction



30% reduction in fixed costs per sample for general tests



#### Main points for improvement

- Efficiency by automation
- Sample admissions
- Testing operations
- Optimal lab network
- Concentrated processing for samples from Kanto region
- Satellite labs conversion to local depots

 Cost reduction for variable costs in general tests, and costs for esoteric tests will be under continuous consideration until the start of operations

#### Schedule



Construction Start Completion Start of Operations February 2019 (subject to change) June 2020 (subject to change) Beginning of FY2021

r											
		FY2019		FY2020		FY2021		FY2022		FY2023	
		1H	2H	1H	2H	1H	2H	1H	2H	1H	2H
First phase											
	General test				Confirm In operation						
	<u>Esoteric test</u> Pathology Biology				Confir	m	In operation				
	Esoteric test										
Second phase	Sequencing Infectious diseases	Confirm In operation									
	Esoteric test Genetic RI							Conf	irm	In operat	ion



# [Contact information] Miraca Holdings Inc. Investor and Public Relations Department Email: mhd.ir@miraca.com

Disclaimer regarding forward-looking statement:

The performance forecast provided in this document is prepared by the management based on currently available information and various hypotheses and ideas including significant risks or uncertainties. Please be aware that the actual performance may turn out to be different from the forecast as a result of various contributing factors.

Factors affecting the performance include, among others, aggravation of the economic situation, fluctuation of the exchange rate, change of regulatory, statutory, and administrative requirements, delayed launch of new products, pressures from the product strategies of competitive companies, and decline of the sales potential of existing products.